The purpose of the study is to compare patients who make changes in lifestyle, with patients who make changes in lifestyle and also take a medicine called metformin, to reduce the risk of metabolic disorders. If you're interested in learning more, you can find the consent forms for the project available to you in your MyHealthConnection account under "Research Opportunities". If you are eligible to participate, the consent form will be available for you to sign up. You can also contact the research team at PragMet@cuanschutz.edu for further information.
Doctors at The University of Colorado Cancer Center treat patients at UCHealth and do research to improve treatment for prostate cancer. Researchers are asking patients diagnosed with prostate cancer and being treated at UCHealth to join the Prostate Cancer Consortium to help them learn more about prostate cancer and possibly contact participants in the future about other studies. Participants who have agreed to be part of the Prostate Cancer Consortium and whose health data has been screened for eligibility are being asked to participate in a research study about how to care for people with prostate cancer who are at risk for metabolic disorders. Main Procedures Involved: As part of the research study, participants may be prescribed a medicine called Metformin, which should be taken twice per day. Metformin is a medicine that works to lower the amount of sugar in the blood of people with diabetes or prediabetes. It does this by lowering the amount of sugar produced in the liver. As part of regular care, all participants will also receive educational materials and periodic email updates about lifestyle changes they can make to improve their overall health and reduce their risk of diabetes. Participants may qualify for a referral to Diabetes prevention program or additional medical care for diabetes, based on the findings. Some of the prevention programs may incur a cost to participants or their insurance. If you decide to join this study, you will continue your usual visits as scheduled with your oncologist. In addition to taking your prescribed doses of Metformin (if you are assigned to that arm), your prostate cancer medical provider will collect routine blood sample each year to monitor your prostate cancer and metabolic condition. Duration of Participation: 10 years
You may be able to join the study if you: - Have a prostate cancer diagnosis - Have a clinical relationship with a participating provider at a UCHealth facility. - Have an active MHC Account - Impaired glucose tolerance and/or overweight, and appropriate to receive metformin, meeting at least one of the following in the last year (timing relative to the consent presentation not start of therapy): - HbA1c of 5.7-6.4 % - BMI equal to or greater than 25 kg/m2 Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov
Principal Investigator